Pharmaceutical Kangde announced that Shanghai Yaoming Kangde New Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, has received the initial share transfer price of 1.54 billion yuan from the transferee. The delivery prerequisites agreed in the “Equity Transfer Agreement” have been met, the transaction has been completed, and the target company is no longer included in the scope of the company's consolidated statements. The transaction is expected to generate net profit of about 960 million yuan after tax, accounting for more than 10% of the company's most recent audited net profit to mother.

Pharmaceutical Kangde announced that Shanghai Yaoming Kangde New Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, has received the initial share transfer price of 1.54 billion yuan from the transferee. The delivery prerequisites agreed in the “Equity Transfer Agreement” have been met, the transaction has been completed, and the target company is no longer included in the scope of the company's consolidated statements. The transaction is expected to generate net profit of about 960 million yuan after tax, accounting for more than 10% of the company's most recent audited net profit to mother.